Pfizer Inc. (NYSE:PFE) Shares Acquired by JB Capital LLC

JB Capital LLC increased its stake in Pfizer Inc. (NYSE:PFEFree Report) by 9.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 168,959 shares of the biopharmaceutical company’s stock after acquiring an additional 14,419 shares during the quarter. JB Capital LLC’s holdings in Pfizer were worth $4,864,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. State Street Corp grew its holdings in shares of Pfizer by 1.9% in the 2nd quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock worth $10,534,558,000 after acquiring an additional 5,374,611 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its position in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the period. Morgan Stanley boosted its position in shares of Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after buying an additional 348,628 shares during the period. Finally, Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter worth $3,150,472,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.10 during trading on Monday, reaching $27.65. The company’s stock had a trading volume of 6,211,507 shares, compared to its average volume of 43,212,367. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The business’s fifty day moving average price is $27.44 and its 200-day moving average price is $29.37. The firm has a market cap of $156.57 billion, a price-to-earnings ratio of 77.31, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a one year low of $25.61 and a one year high of $42.22.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Truist Financial reduced their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. UBS Group reduced their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Finally, Barclays reduced their price objective on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $36.88.

Check Out Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.